Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Documenti analoghi

• Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer
  di: Rotolo, Federico, et al.
  Pubblicazione: (2018)
• Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
  di: Shepherd, Frances A., et al.
  Pubblicazione: (2017)
• Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
  di: Devarakonda, Siddhartha, et al.
  Pubblicazione: (2018)
• Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
  di: Shepherd, Frances A., et al.
  Pubblicazione: (2013)
• Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection
  di: Tsao, Ming-Sound, et al.
  Pubblicazione: (2015)